Welcome to our dedicated page for Dermata Therapeutics news (Ticker: DRMA), a resource for investors and traders seeking the latest updates and insights on Dermata Therapeutics stock.
Dermata Therapeutics, Inc. develops dermatologic solutions and is repositioning its business around direct-to-consumer skincare under the Tome brand. Company updates center on OTC skincare concepts, including once-weekly acne and skin renewal products that use the company's Bioneedle and Spongilla technologies, as well as intellectual-property developments for Bioneedle Delivery System applications involving dermal fillers, botulinum toxin and hyperhidrosis.
Recurring Dermata news also includes financial results, private placements and at-the-market equity activity, along with management, marketing and board developments tied to its shift from pharmaceutical development toward consumer skincare products.
Dermata Therapeutics (NASDAQ:DRMA) will host a virtual investor event on November 19, 2021, at 4:30 PM ET to present results of its DMT410 Phase 1b study targeting multiple aesthetic skin conditions. The event features presentations from Dr. Christopher Nardo and Gerry Proehl, focusing on the proof of concept evaluation initially shared at the American Society for Dermatologic Surgery meeting. DMT410 utilizes Dermata's Spongilla technology to deliver botulinum toxin topically and may offer a new treatment avenue for skin conditions.
Dermata Therapeutics (NASDAQ:DRMA) announced positive results from its Phase 1b trial of DMT310 for treating mild-to-moderate psoriasis. The study showed that 29.6% of patients achieved a Physician's Global Assessment (PGA) score of 0 or 1, while 25.9% had a Psoriasis Area Severity Index (PASI) score of 0 or 1 after 8 weeks. Additionally, there was a 19.6% reduction in pruritus. The treatment was reported to be safe with few adverse events. Dermata plans to advance DMT310 in further clinical investigations.
Dermata Therapeutics (Nasdaq:DRMA) announced an oversubscribed $18 million IPO, enhancing its clinical development focus. The company aims to release topline data from its DMT310 Phase 1b study for psoriasis in 4Q 2021 and initiate a Phase 2 study for rosacea later this year. Financial results reveal cash reserves of $427,202 as of June 30, 2021, down from $530,400 at year-end 2020. R&D expenses rose significantly to $867,197 for Q2 2021 from $411,949 in Q2 2020, reflecting increased clinical trial costs. General expenses also increased sharply, highlighting rising operational costs.
Dermata Therapeutics (NASDAQ:DRMA)(NASDAQ:DRMAW) will present efficacy and safety data from a Phase 1b study evaluating DMT410 as a new topical delivery mechanism for botulinum toxin aimed at aesthetic skin conditions at the ASDS 2021 Annual Meeting on November 19-21, 2021. The study involved 10 patients receiving DMT410, comprising a topical application of Spongilla powder followed by botulinum toxin, with observed outcomes over 16 weeks. The presentation signifies Dermata's commitment to innovative treatments in dermatology.
Dermata Therapeutics (NASDAQ:DRMA, DRMAW) announced the appointment of Kyri Van Hoose as Senior Vice President and Chief Financial Officer, succeeding Thomas Insley, who will retire but remain as a financial consultant. With over 20 years of finance experience in the life sciences, Ms. Van Hoose aims to drive Dermata's growth and support development programs for DMT310 and DMT410. CEO Gerry Proehl expressed confidence in her ability to enhance corporate value and navigate the company’s future as a public entity.
Dermata Therapeutics has successfully completed its initial public offering, closing on the sale of 2,571,428 shares of common stock and accompanying warrants at $7.00 per share, raising approximately $18 million. The company intends to utilize the proceeds to further develop its clinical products, including DMT310 and DMT410, targeting conditions such as rosacea, psoriasis, and aesthetic indications. The offering included an option for underwriters to purchase additional shares, which has been partially exercised. Shares began trading on the Nasdaq under the symbols DRMA and DRMAW.